anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Traumatic brain injury (TBI) contributes to 50% of all trauma deaths. The mortality rate for adults following severe TBI (Glasgow Coma Scale \< 9) is estimated to be 33%. There is currently no therapy to reverse the primary injury associated with TBI. Over the past 10 years there has been a growing body of literature supporting the use of various progenitor cell types to treat acute neurological injuries such as TBI and stroke. Neural stem cells (adult and embryonic), mesenchymal stromal and multipotent adult progenitor cells, and bone marrow mononuclear cells (from which MSC and MAPCs are derived) have all shown efficacy in pre-clinical models of TBI/stroke through various mechanisms; however, few groups believe that true neural replacement and integration are the putative mechanisms involved in the observed efficacy. More likely is that the progenitor cell populations are modifying the regional response to injury (inflammatory/reparative vs. regenerative), resulting in improved functional outcomes. Our primary hypothesis is that bone marrow mononuclear cell (BMMNC) autologous transplantation after TBI is safe (harvest and infusion related toxicity) after TBI. Our secondary hypothesis is that functional outcomes measures will improve after BMMNC infusion, (3) BMMNC infusion will reduce BBB permeability, (4) BMMNC is neuroprotective and preserves grey matter and white matter volumes after TBI.

Patients, ages18 to 55 years old, admitted to Memorial Hermann Hospital Trauma Center with Glasgow Coma Scores (GCS) of 5 to 8 will be screened. Those patients meeting inclusion/exclusion criteria (or their Legal Authorized Representative \[LAR\]) will be offered consent to participate. This is a dose-escalation study consisting of 4 cohorts including a control group (5 subjects/cohort). The first five subjects will not undergo the bone marrow harvest procedure; though they will be followed and treated the same as the other study participants and complete all follow-up procedures. Subjects 6-10 will receive the lowest dose target of 6X106 mononuclear cells/kilogram body weight. Subjects 11-15 will receive 9x106 mononuclear cells/kilogram body weight, and lastly Subjects 16-20 will receive 12X106 mononuclear cells/kilogram body weight. The study is NOT powered to detect functional measures of efficacy. However, estimates can be made regarding potential treatment effect sizes to allow rational power analyses for the follow-on Phase II study. This study should determine if bone marrow harvest, BMMNC separation, and reinfusion is safe in adults with acute, severe TBI.
The invention relates to a light-cured composite resin for an oral cavity by using single crystal diamond as a filler, which belongs to the field of a medical oral cavity material. The resin comprisesThe invention relates to a light-cured composite resin for an oral cavity by using single crystal diamond as a filler, which belongs to the field of a medical oral cavity material. The resin comprises a resin matrix and the filler, wherein the filler comprises coupling barium glass powder and coupling diamond. The composite resin is characterized in that the coupling diamond comprises coupling sina resin matrix and the filler, wherein the filler comprises coupling barium glass powder and coupling diamond. The composite resin is characterized in that the coupling diamond comprises coupling sin gle crystal diamond which accounts for 15-25 percent of the total weight of the composite resin, coupling glomerocryst diamond which accounts for 0-1 percent of the total weight of the composite resingle crystal diamond which accounts for 15-25 percent of the total weight of the composite resin, coupling glomerocryst diamond which accounts for 0-1 percent of the total weight of the composite resinand coupling nanometer diamond which accounts for 0-1 percent of the total weigh of the composite resin. The single crystal diamond is added as the functional filler, so that the flexural strength an  and coupling nanometer diamond which accounts for 0-1 percent of the total weigh of the composite resin. The single crystal diamond is added as the functional filler, so that the flexural strength and the micro hardness of the prepared composite resin are observably increased, the maximum flexural strength value of the composite resin, which can reach 112.5MPa, can satisfy the requirement in a nad the micro hardness of the prepared composite resin are observably increased, the maximum flexural strength value of the composite resin, which can reach 112.5MPa, can satisfy the requirement in a national medical standard that flexural strength value of the composite resin should be equal to or greater than 50 MPa, even can satisfy the requirement for the strength (greater than 80 MPa) of occlustional medical standard that flexural strength value of the composite resin should be equal to or greater than 50 MPa, even can satisfy the requirement for the strength (greater than 80 MPa) of occlusal restoring materials.                                                                                                                                                                                 al restoring materials.
Stages I-IV clear cell sarcoma): After conventional surgery (nephrectomy), patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
People with social medial accounts (e.g. Facebook) will receive a message about the study (e.g. via an age and geospatially targeted Facebook ad) and have the option to enroll in the study if meeting eligibility criteria, with some participating in online or telephone follow-up. This arms will serve as an experimental arm for assessing study aim 2 and as a control arm for study aim 1.
The intricate architecture of the intestinal epithelium, crucial for nutrient absorption, is constantly threatened by environmental factors. The epithelium undergoes rapid turnover, which is essential for maintaining homeostasis, under the control of intestinal stem cells (ISCs). The central regulator, Wnt/β-catenin signaling plays a key role in intestinal integrity and turnover. Despite its significance, the impact of environmental factors on this pathway has been largely overlooked. This study, for the first time, investigates the influence of Cd on the intestinal Wnt signaling pathway using a mouse model. In this study, male BALB/c mice were administered an environmentally relevant Cd dose (0.98 mg/kg) through oral gavage to investigate the intestinal disruption and Wnt signaling pathway. Various studies, including histopathology, immunohistochemistry, RT-PCR, western blotting, ELISA, intestinal permeability assay, and flow cytometry, were conducted to study Cd-induced changes in the intestine. The canonical Wnt signaling pathway experienced significant downregulation as a result of sub-chronic Cd exposure, which caused extensive damage throughout the small intestine. Increased intestinal permeability and a skewed immune response were also observed. To confirm that Wnt signaling downregulation is the key driver of Cd-induced gastrointestinal toxicity, mice were co-exposed to LiCl (a recognized Wnt activator) and Cd. The results clearly showed that the harmful effects of Cd could be reversed, which is strong evidence that Cd mostly damages the intestine through the Wnt/β-catenin signalling axis. In conclusion, this research advances the current understanding of the role of Wnt/β catenin signaling in gastrointestinal toxicity caused by diverse environmental pollutants.
Antimicrobial compositions having synergistic combinations of octoxyglycerin and at least one other antimicrobial agent in formulations which are more effective than prior art compositions without causing increased irritation to the skin of the average user. In certain embodiments, skin irritation may be minimized by low concentrations of antimicrobials and/or the presence of soothing compounds such as zinc. Preferred embodiments include combinations of octoxyglycerin, a quaternary compound, and at least one other antimicrobial agent. Without being bound to any particular theory, it is hypothesized that the unexpected antimicrobial effectiveness of combinations of octoxyglycerin may result from an enhancement of the permeability of microbes to antimicrobials caused by octoxyglycerin. Hydroalcoholic gel composition containing alcohol, water, hydrogel, and emollient or emulsifier, wherein the composition has a viscosity of below 2000 centipoises at between 20 and 40 ~C.  This skin-friendly hydroalcoholic gel composition, which can be further combined with silicone polymer, emollient solvent, thickening agent and antimicrobial agent, enhances rapid and long-term antimicrobial efficacy.
Allopurinol, USP is a xanthine oxidase inhibitor. It has the following structural formula:

Allopurinol, USP is known chemically as 1, 5-dihydro-4H-pyrazolo [3, 4-d]pyrimidin-4-one and it has a molecular weight of 136.11 g/mol. Its solubility in water at 37°C is 80.0 mg/dL and is greater in an alkaline solution. It is a xanthine oxidase inhibitor which is administered orally.

Allopurinol Tablets USP, 100 mg and 300 mg contain the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized corn starch and sodium lauryl sulfate. In addition, the 300 mg strength also contains FD&C Yellow No. 6.
### Oral Contraception

Combination oral contraceptives (COCs) act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increases the difficulty of sperm entry into the uterus) and the endometrium (which reduces the likelihood of implantation).

Drospirenone is a spironolactone analogue with antimineralocorticoid activity. Preclinical studies in animals and in vitro have shown that drospirenone has no androgenic, estrogenic, glucocorticoid, or antiglucocorticoid activity. Preclinical studies in animals have also shown that drospirenone has antiandrogenic activity.

### Acne

Acne vulgaris is a skin condition with a multifactorial etiology including androgen stimulation of sebum production. While the combination of ethinyl estradiol and drospirenone increases sex hormone binding globulin (SHBG) and decreases free testosterone, the relationship between these changes and a decrease in the severity of facial acne in otherwise healthy women with this skin condition has not been established. The impact of the antiandrogenic activity of drospirenone on acne is not known.
Root canal treatment will be performed in posterior teeth.In this group the root canal will be dried with paper points and obturated with using gutta-percha cones and zinc oxide eugenol sealer. Coronal access cavities will be restored with direct composite restorations using dentinal adhesives and universal composite resin . Postoperative VAS scores will be recorded after 24 h and 48 h to determine their post-operative pain.
Sleep disturbance usually accompanies anxiety disorders and exacerbates their incidence rates. The precise circuit mechanisms remain poorly understood. Here, we found that glutamatergic neurons in the posteroventral medial amygdala (MePVGlu neurons) are involved in arousal and anxiety-like behaviors. Excitation of MePVGlu neurons not only promoted wakefulness but also increased anxiety-like behaviors. Different projections of MePVGlu neurons played various roles in regulating anxiety-like behaviors and sleep-wakefulness. MePVGlu neurons promoted wakefulness through the MePVGlu/posteromedial cortical amygdaloid area (PMCo) pathway and the MePVGlu/bed nucleus of the stria terminals (BNST) pathway. In contrast, MePVGlu neurons increased anxiety-like behaviors through the MePVGlu/ventromedial hypothalamus (VMH) pathway. Chronic sleep disturbance increased anxiety levels and reduced reparative sleep, accompanied by the enhanced excitability of MePVGlu/PMCo and MePVGlu/VMH circuits but suppressed responses of glutamatergic neurons in the BNST. Inhibition of the MePVGlu neurons could rescue chronic sleep deprivation-induced phenotypes. Our findings provide important circuit mechanisms for chronic sleep disturbance-induced hyperarousal response and obsessive anxiety-like behavior and are expected to provide a promising strategy for treating sleep-related psychiatric disorders and insomnia.
Participants will be consented prior to resection of HCC and CRLM. Genomic sequencing of patient's blood and resected tumour will be performed, followed by tumour NA prediction and production. Patients will undergo venesection to generate DCs which will be pulsed with autologous NAs to produce the vaccine. 10 dose of intra-dermal NA DC vaccine will be administered every 2 weeks together with IV nivolumab (starting from the second vaccine dose). Patients will subsequently continue on adjuvant nivolumab to complete 1 year of treatment.

Efficacy will be evaluated based on relapse-free survival (RFS) at 24 months from surgery and the analyses of specific anti-NA immune responses of autologous peripheral T cells by ELISPOT and/or ICS assays. Safety data will also be obtained for patients who have received at least one dose of treatment.
BACKGROUND AND OBJECTIVES: While the health promoting effects of green tea polyphenols have been identi-fied among adult, research on children is scarce probably due to safety concerns about caffeine. This study aims to evaluate the safety of decaffeinated green tea polyphenols (DGTP) supplementation in girls with obesity and lay the foundation for its application in children population.
METHODS AND STUDY DESIGN: This 12-week randomized, double-blinded, parallel-controlled trial was performed among 62 girls with obesity aged 6 to 10 years old. Participants were allocated to take 400 mg/d DGTP (DGTP group, n = 31) or isodose placebo (Control group, n = 31) at random. Anthropometric measurements and biochemical parameters including hepatic and renal function indicators, serum minerals concentrations, and routine blood parameters, were measured at baseline and the end of this trial. DGTP intake diary was required for each participant to record any abnormal reactions.
RESULTS: After the 12-week supplementation, compared to Control group, the uric acid concentration in DGTP group showed a significant decrease (-48.0 ± 83.2 vs -0.01 ± 69.1, μmol/L), within the normal range. Regarding other biochemical indicators, there were no significant differences in changed values between the two groups. Throughout the trial, no adverse effects were reported in either group.
CONCLUSIONS: This study indicated that the supplementation of 400 mg/d DGTP for 12 weeks had no adverse health effects in girls with obesity, providing evidence for the DGTP adoption in children research.
Participants in this arm will not experience any intervention during a 4 week period of time. Participants will experience their standard medical care.
PURPOSE:To obtain an immunostimulant containing a diglyceride compound as an active component, having excellent immunostimulating activity and safety and capable of effectively stimulating immune response at infection, etc. CONSTITUTION:This immunostimulant contains, as an active component, a diglyceride of the formula (two groups of R<1> to R<2> are acyl groups derived from saturated or unsaturated aliphatic acids of 12-22C and the rest of them is H). The immunostimulant can be formulated as a tablet, a capsule, powder, granules, syrup, an injection, an enteral formulation, etc. The daily dose for an adult is conventionally 1-70g as diglyceride. A diglyceride of the formula is obtained by subjecting a mixture of fat and oil and glyceral to transesterification in the presence of a hydroxide compound of an alkali metal and/or an alkaline earth metal. The immunostimulant is free from a side effect even at daily administration or intake and free from an influence on the taste when added to foods, etc.
A substituted benzene propylene derivative and the salt are provided, which is that the phenylacrylate substituted by the corresponding group gains the correspondingly substituted phenylallyl compound through the deoxidization of the lithium aluminium hydride and the aluminium trichloride compound. The invention has certain selective cytotoxicity activeness compound from the natural erucic based alcohol compound and has low toxic effect on the normal cells, while the compounds reconstructed by structure and the important midbodies all have better cytotoxicity activeness and can be prepared in the drugs preventing and curing the tumor diseases. The prepared drugs contain the drug excipients or carriers allowed by the preparation. The drug preparation is in a form of liquid, solid, aerial fog spray, drop, gelatin pearl, nano, controlled release and sustained-release preparation. The compound related to by the invention has simple synthetic method and lower cost, therefore having feasible marketalization prospect. The invention has the above general formula.
PURPOSE:To obtain a blood triglyceride depressing agent containing a fat emulsion containing prostaglaiudin E1 as an active component and exhibiting excell. ent sustained releasability, durability, local (focus) accumulation property and storage stability. CONSTITUTION:This blood triglyceride depressing agent contains a fat emulsion containing prostaglandin E1 or its derivative as an active component. The fat emulsion is preferably a mixture of 5-50%(W/V) of vegetable oil, 5-30 pts.wt. (based on 100 pts.wt. of the vegetable oil) of a phospholipid and a proper amount of water. The agent is preferably used in the form of an intravenous injection and preferably 1-50mug of the agent is injected at a rate of 0.02-0.2ng/kg/min.
PURPOSE:To provide the hospital information system which efficiently uses a mobile terminal by online and offline. CONSTITUTION:This system consists of network cables 1-1 to 1-3, bridges 2-1 and 2-2 which join the network cables, and LAN cards 4-1 to 4-5. Plural LAN cards are connected to each network cable with respect to the number of connected LAN cards 4-1 to 4.5. A server 3 which manages hospital information is connected to the network cable 1-1. When a mobile terminal 5 is connected to the LAN card 4-1 in this network, the mobile terminal 5 can communicate with all of computers of the network. For example, it can communicate with even the servers 3 in another cable segment through the bridge 2-1. Even if the mobile terminal is moved, LAN cards are not moved, and tables of bridges are not changed; and therefore, efficient transmission is possible.
The present invention relates to a traditional Chinese medicine for treating non-alcoholic simple fatty liver, and a preparation method thereof. The morbidity of fatty liver is constantly increased in metabolic hepatopathy in recent years, fatty liver becomes the second largest hepatopathy second only to virus hepatitis, and fatness, diabetes and alcoholism are three big causes of diseases of fatty liver. The present invention is composed of seaweed, danshen root, peach seed, india madder root, hawthorn, semen cassiae, bunge cherry seed, water plantain, earthworm, bear gall, etc., wherein the seaweed is matched with the hawthorn and the semen cassiae to soften hard masses and eliminate phlegm; the danshen root is matched with the peach seed and the india madder root to activate blood circulation and dissipate phlegm; the bunge cherry seed and the water plantain clear damp, promote diuresis, and eliminate pathogenic factors; the earthworm enhances collateral dredging force; the bear gall is used for leading action; all of the traditional Chinese medicines matching with each other can eliminate fat, dissolve turbidity, soothe the liver and dredge collateral. The present invention has the advantages of precise prescription, scientific compatibility and conspicuous curative effect. 50 fatty liver patients are clinically observed preliminarily, wherein 25 patients have obvious effect, 21 patients have general effect, and 4 patients have no effect. The excellence rate is 50%, the total effective rate is 92%, and adverse reaction is not found in the period in a medicine.
Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
Survivors of central nervous system injury commonly present with spastic hypertonia. The affected muscles are hyperexcitable and can display involuntary static muscle tone and an exaggerated stretch reflex. These symptoms affect posture and disrupt activities of daily living. Symptoms are typically measured using subjective manual tests such as the Modified Ashworth Scale; however, more quantitative measures are necessary to evaluate potential treatments. The hands are one of the most common targets for intervention, but few investigators attempt to quantify symptoms of spastic hypertonia affecting the fingers. An Isometric Force Pillow (IFP) is provided herein to quantify involuntary grip force. This lightweight, computerized tool provides a holistic measure of finger flexion force and can be used in various orientations for clinical testing and to measure the impact of assistive devices.
PURPOSE: To determine factors influencing patient satisfaction scores in recipients of refractive surgery.
METHODS: In this prospective survey-based study, patients who had refractive surgery at an outpatient refractive clinic completed a survey of selected questions from the Press Ganey survey and the National Eye Institute Visual Function Questionnaire-25. Correlation between patient-specific variables and survey questions were assessed using Student's t-tests.
RESULTS: Fifty-three patients were recruited over a 3-year period. Most were male (55%) and middle aged (mean age: 34 years). Eleven percent underwent photorefractive keratectomy surgery and the rest had laser in situ keratomileusis, with no complications. Twenty-four percent of surveyed patients reported mild to moderate eye pain postoperatively, with the rest reporting no pain. All patients reported a full score for overall satisfaction.
CONCLUSIONS: This study found persistent high patient satisfaction score across a variation of characteristics, suggesting that optimal scores are mainstay after refractive surgery procedures with excellent visual outcomes, independent of patient clinical and sociodemographic characteristics. [J Refract Surg. 2024;40(8):e539-e543.].